Human herpesvirus 6 peptide-HLA complex (HHV-6 pHLA)

Human herpesvirus 6 (HHV-6) peptide-HLA complexes are molecular assemblies presented on the surface of infected host cells, consisting of viral-derived peptides non-covalently bound to Human Leukocyte Antigen (HLA) molecules (Iampietro et al., 2014, Journal of Virology). These complexes are critical for the immune system's ability to detect intracellular viral replication, as they are specifically recognized by the T-cell receptors (TCRs) of CD8+ cytotoxic T cells and CD4+ helper T cells (de Pagter et al., 2013, Antiviral Research). HHV-6, which includes the species HHV-6A and HHV-6B, is a ubiquitous betaherpesvirus that establishes latency in various tissues and can reactivate in immunocompromised patients, leading to severe conditions such as encephalitis, pneumonitis, and bone marrow suppression (Papadopoulou et al., 2014, Science Translational Medicine). In clinical development, these complexes are the primary targets for adoptive cell therapies, such as virus-specific T cells (VSTs), which aim to provide or restore cellular immunity in transplant recipients (AlloVir, 2023, Company Website). Understanding the specific immunodominant peptides, such as those derived from the U54 or U90 proteins, and their HLA restriction is essential for the design of targeted immunotherapies and vaccines. Furthermore, these complexes are of interest in autoimmune research due to potential molecular mimicry between HHV-6 antigens and host proteins like myelin basic protein (MBP), which may contribute to the pathogenesis of multiple sclerosis (Soldan et al., 1997, Nature Medicine).

Other names

HHV-6 pMHCHHV-6 peptide-MHC complexHuman betaherpesvirus 6 peptide-HLA complexHHV-6 antigen-HLA complex

T-cell receptor (TCR) mediated recognition of viral peptides presented by HLA molecules, leading to the activation of cytotoxic T lymphocytes and the lysis of infected cells.